Novo Nordisk (NYSE:NVO) is one of the stocks that should double in 3 years. On February 4, Novo Nordisk delivered 10% sales growth in 2025, driven by its obesity and diabetes portfolios. The company’s obesity care sales reached DKK 82 billion, marking a substantial increase since 2019 and expanding its reach to 16 million additional patients. Financial results surpassed expectations with a reported EPS of $1, although the gross margin decreased to 81% due to manufacturing acquisitions and restructuring cos ...